Lower uric acid and adequate hydration are associated with lower risk of febrile neutropenia following autologous bone marrow transplantation in patients with lymphoma

Babak Nejati; Zohreh Kourehpaz; Roya Dolatkhah; Mojtaba Varshochi; Maryam Farmani; Alireza Parviz

doi:10.20883/medical.e836

Authors

Babak Nejati Internal Medicine Department, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0002-6861-3175
Zohreh Kourehpaz Internal Medicine Department, Tabriz University of Medical Sciences, Tabriz, Iran https://orcid.org/0000-0002-7805-9761
Roya Dolatkhah Iran https://orcid.org/0000-0002-6897-7120
Mojtaba Varshochi Iran
Maryam Farmani Iran
Alireza Parviz Iran

DOI:

https://doi.org/10.20883/medical.e836

Keywords:

febrile neutropenia, autologous bone marrow transplantation, lymphoma, infection

Abstract

Background. Despite the promising results of autologous bone marrow transplantation (BMT) in patients with lymphoma, infectious complications limit its positive outcomes. This study evaluated the incidence and associated factors of febrile neutropenia (FN) following BMT in patients with lymphoma.

Materials and methods. The study consecutively included 147 patients with lymphoma who were candidates for BMT. Clinical and laboratory results were recorded, and after BMT, the occurrence of FN was investigated through the daily evaluation of neutrophil count and body temperature.

Results. On average, FN occurred in 91 patients (61.9%) after 12.77 ± 2.45 days after BMT. Lower fluid balance was associated with a higher risk of FN (lowest adjusted odds ratio [OR] at day -2 = 0.602, 95% confidence interval [CI] = 0.299 – 0.870, p-value = 0.007). The higher uric acid level was associated with a higher risk of FN (highest adjusted OR at day -10 = 1.617, 95% CI = 1.328 – 1.963, p-value = 0.035). LDH was also positively correlated with FN (highest adjusted OR at day 0 = 1.501, 95% CI = 1.198 – 2.104, p-value = 0.004).

Conclusions. Adequate hydration of the patients is of paramount importance for preventing FN in patients who receive BMT. Furthermore, uric acid and LDH could be considered in future studies for the risk stratification of FN.

Downloads

Download data is not yet available.

References

Mugnaini EN, Ghosh N. Lymphoma. Prim Care. 2016 Dec;43(4):661-675. doi: 10.1016/j.pop.2016.07.012.. DOI: https://doi.org/10.1016/j.pop.2016.07.012

Zhou L, Deng Y, Li N, Zheng Y, Tian T, Zhai Z, et al. Global, regional, and national burden of Hodgkin lymphoma from 1990 to 2017: estimates from the 2017 Global Burden of Disease study. J Hematol Oncol. 2019;12(1):107. doi: 10.1186/s13045-019-0799-1. DOI: https://doi.org/10.1186/s13045-019-0799-1

Somi MH, Dolatkhah R, Sepahi S, Belalzadeh M, Sharbafi J, Abdollahi L, et al. Cancer incidence in the East Azerbaijan province of Iran in 2015-2016: results of a population-based cancer registry. BMC Public Health. 2018;18(1):1266. doi: 10.1186/s12889-018-6119-9. DOI: https://doi.org/10.1186/s12889-018-6119-9

Jiang Y, Hematology Department, First Affiliated Hospital of Nanchang University, Jiangxi, China, Zhen Y, Xu Q, He D, Chen G, et al. Bone marrow versus peripheral blood stem cell transplant in lymphoma: A systematic review and meta-analysis. Exp Clin Transplant. 2017; doi: 10.6002/ect.2017.0073. DOI: https://doi.org/10.6002/ect.2017.0073

Sarashina T, Yoshida M, Iguchi A, Okubo H, Toriumi N, Suzuki D, et al. Risk factor analysis of bloodstream infection in pediatric patients after hematopoietic stem cell transplantation. J Pediatr Hematol Oncol. 2013;35(1):76–80. doi: 10.1097/MPH.0b013e3182677f35. DOI: https://doi.org/10.1097/MPH.0b013e3182677f35

Blennow O, Ljungman P, Sparrelid E, Mattsson J, Remberger M. Incidence, risk factors, and outcome of bloodstream infections during the pre-engraftment phase in 521 allogeneic hematopoietic stem cell transplantations. Transpl Infect Dis. 2014;16(1):106–14. doi: 10.1111/tid.12175. DOI: https://doi.org/10.1111/tid.12175

Dandoy CE, Ardura MI, Papanicolaou GA, Auletta JJ. Bacterial bloodstream infections in the allogeneic hematopoietic cell transplant patient: new considerations for a persistent nemesis. Bone Marrow Transplant. 2017;52(8):1091–106. doi: 10.1038/bmt.2017.14. DOI: https://doi.org/10.1038/bmt.2017.14

Mikulska M, Del Bono V, Raiola AM, Bruno B, Gualandi F, Occhini D, et al. Blood stream infections in allogeneic hematopoietic stem cell transplant recipients: reemergence of Gram-negative rods and increasing antibiotic resistance. Biol Blood Marrow Transplant. 2009;15(1):47–53. doi: 10.1016/j.bbmt.2008.10.024. DOI: https://doi.org/10.1016/j.bbmt.2008.10.024

Kikuchi M, Akahoshi Y, Nakano H, Ugai T, Wada H, Yamasaki R, et al. Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2015;17(1):56–65. doi: 10.1111/tid.12345. DOI: https://doi.org/10.1111/tid.12345

Kumar G, Ahmad S, Taneja A, Patel J, Guddati AK, Nanchal R, et al. Severe sepsis in hematopoietic stem cell transplant recipients. Crit Care Med. 2015;43(2):411–21. doi: 10.1097/CCM.0000000000000714. DOI: https://doi.org/10.1097/CCM.0000000000000714

Serody JS, Berrey MM, Albritton K, O’Brien SM, Capel EP, Bigelow SH, et al. Utility of obtaining blood cultures in febrile neutropenic patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2000;26(5):533–8. doi: 10.1038/sj.bmt.1702535. DOI: https://doi.org/10.1038/sj.bmt.1702535

Mitchell AE, Derrington P, Turner P, Hunt LP, Oakhill A, Marks DI. Gram-negative bacteraemia (GNB) after 428 unrelated donor bone marrow transplants (UD-BMT): risk factors, prophylaxis, therapy and outcome. Bone Marrow Transplant. 2004;33(3):303–10. doi: 10.1038/sj.bmt.1704338. DOI: https://doi.org/10.1038/sj.bmt.1704338

Dandoy CE, Haslam D, Lane A, Jodele S, Demmel K, El-Bietar J, et al. Healthcare burden, risk factors, and outcomes of mucosal barrier injury laboratory-confirmed bloodstream infections after stem cell transplantation. Biol Blood Marrow Transplant. 2016;22(9):1671–7. doi: 10.1016/j.bbmt.2016.06.002. DOI: https://doi.org/10.1016/j.bbmt.2016.06.002

Kanda J, Mizumoto C, Ichinohe T, Kawabata H, Saito T, Yamashita K, et al. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2011;46(2):208–16. doi: 10.1038/bmt.2010.108. DOI: https://doi.org/10.1038/bmt.2010.108

Trinkaus MA, Lapinsky SE, Crump M, Keating A, Reece DE, Chen C, et al. Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit. Bone Marrow Transplant. 2009;43(5):411–5. doi: 10.1038/bmt.2008.336. DOI: https://doi.org/10.1038/bmt.2008.336

Handin RI, Lux SE, Stossel TP. principles and practice of hematology. Lippincott Williams & Wilkins; 2003..

Sahai T, Hauser N, Mukkamalla SKR, Menendez AG, Roberts TF, Tandon R. Outcomes of febrile neutropenia following hematopoietic stem cell transplantation. J Clin Oncol. 2016;34(15_suppl):e18562–e18562. doi: 10.1200/jco.2016.34.15_suppl.e18562. DOI: https://doi.org/10.1200/JCO.2016.34.15_suppl.e18562

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011;52(4):e56-93. doi: 10.1093/cid/cir073. DOI: https://doi.org/10.1093/cid/cir073

Gomez L, Garau J, Estrada C, Marquez M, Dalmau D, Xercavins M, et al. Ciprofloxacin prophylaxis in patients with acute leukemia and granulocytopenia in an area with a high prevalence of ciprofloxacin-resistant Escherichia coli: Ciprofloxacin Prophylaxis and Granulocytopenia. Cancer. 2003;97(2):419–24. doi: 10.1002/cncr.11044. DOI: https://doi.org/10.1002/cncr.11044

Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother. 2008;61(3):721–8. doi: 10.1093/jac/dkm514. DOI: https://doi.org/10.1093/jac/dkm514

Prabhu RM, Piper KE, Litzow MR, Steckelberg JM, Patel R. Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis. 2005;24(12):832–8. doi: 10.1007/s10096-005-0037-3. DOI: https://doi.org/10.1007/s10096-005-0037-3

Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology-oncology unit. Eur J Clin Microbiol Infect Dis. 2008;27(3):209–16. doi: 10.1007/s10096-007-0428-8. DOI: https://doi.org/10.1007/s10096-007-0428-8

Kanda J, Ichinohe T, Saito T, Yamashita K, Kondo T, Ishikawa T, et al. Impact of discontinuing fluoroquinolone prophylaxis on early mortality after allogeneic marrow or peripheral blood SCT with myeloablative conditioning. Bone Marrow Transplant. 2010;45(8):1369–71. doi: 10.1038/bmt.2009.344. DOI: https://doi.org/10.1038/bmt.2009.344

Celebi H, Akan H, Akçağlayan E, Ustün C, Arat M. Febrile neutropenia in allogeneic and autologous peripheral blood stem cell transplantation and conventional chemotherapy for malignancies. Bone Marrow Transplant. 2000;26(2):211–4. doi: 10.1038/sj.bmt.1702503. DOI: https://doi.org/10.1038/sj.bmt.1702503

Akan H, Koç H, Arslan O, Beksaç M, Ilhan O, Gürman G, et al. Febrile neutropenia in a bone marrow transplantation unit. Int J Antimicrob Agents. 1997;8(2):127–30. doi: 10.1016/s0924-8579(96)00364-0. DOI: https://doi.org/10.1016/S0924-8579(96)00364-0

Zhang W-X, Zhao Q-Y, Huang H-Q. Febrile neutropenic infection occurred in cancer patients undergoing autologous peripheral blood stem cell transplantation. Transplant Proc. 2015;47(2):523–7. doi: 10.1016/j.transproceed.2015.01.013. DOI: https://doi.org/10.1016/j.transproceed.2015.01.013

Abe O, Abe R, Enomoto K, Kikuchi K, Koyama H, Masuda H. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366(9503):2087–106.. DOI: https://doi.org/10.1016/S0140-6736(05)67887-7

El Din U, Salem MM, Abdulazim DO. Uric acid in the pathogenesis of metabolic, renal, and cardiovascular diseases: A review. Journal of advanced research. 2017;8(5):537–48.. DOI: https://doi.org/10.1016/j.jare.2016.11.004

Wasserman A, Shnell M, Boursi B, Guzner-Gur H. Prognostic significance of serum uric acid in patients admitted to the Department of Medicine. Am J Med Sci. 2010;339(1):15–21. doi: 10.1097/MAJ.0b013e3181bbb647. DOI: https://doi.org/10.1097/MAJ.0b013e3181bbb647

Habibollahi P, Garjani A, Shams Vahdati S, Sadat-Ebrahimi S-R, Parnianfard N. Severe complications of tramadol overdose in Iran. Epidemiol Health. 2019;41:e2019026. doi: 10.4178/epih.e2019026. DOI: https://doi.org/10.4178/epih.e2019026

Kalaycio M, Rybicki L, Pohlman B, Dean R, Sweetenham J, Andresen S, et al. Elevated lactate dehydrogenase is an adverse predictor of outcome in HLA-matched sibling bone marrow transplant for acute myelogenous leukemia. Bone Marrow Transplant. 2007;40(8):753–8. doi: 10.1038/sj.bmt.1705811. DOI: https://doi.org/10.1038/sj.bmt.1705811

Beetz R. Mild dehydration: a risk factor of urinary tract infection? Eur J Clin Nutr. 2003;57 Suppl 2(S2):S52-8. doi: 10.1038/sj.ejcn.1601902. DOI: https://doi.org/10.1038/sj.ejcn.1601902

Fujii K, Aoyama M, Shinagawa K, Matsuo K, Takenaka K, Ikeda K, et al. Risk of neutropenic fever and early infectious complications after autologous peripheral blood stem cell transplantation for malignant diseases. Int J Hematol. 2002;76(2):186–91. doi: 10.1007/bf02982583. DOI: https://doi.org/10.1007/BF02982583

Pérez-Simón JA, Martín A, Caballero D, Corral M, Nieto MJ, Gonzalez M, et al. Clinical significance of CD34+ cell dose in long-term engraftment following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 1999;24(12):1279–83. doi: 10.1038/sj.bmt.1702066. DOI: https://doi.org/10.1038/sj.bmt.1702066

Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant. 1996;18(2):355–9..

Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, et al. Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis. 1999;28(2):256–66. doi: 10.1086/515103. DOI: https://doi.org/10.1086/515103

O’Brien SN, Blijlevens NMA, Mahfouz TH, Anaissie EJ. Infections in patients with hematological cancer: recent developments. Hematology Am Soc Hematol Educ Program. 2003;2003(1):438–72. doi: 10.1182/asheducation-2003.1.438. DOI: https://doi.org/10.1182/asheducation-2003.1.438

Cainelli F. Transplant infections. Lancet. 2004;363(9409):666. doi: 10.1016/s0140-6736(04)15618-3. DOI: https://doi.org/10.1016/S0140-6736(04)15618-3